Company Study of Walvax Biotechnology Co, Ltd.,2012
  • May/2012
  • Hard Copy
  • USD $379
  • Pages:13
  • Single User License
    (PDF Unprintable)       
  • USD $329
  • Code: ZYM028
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $589
  • Hard Copy + Single User License
  • USD $429
Walvax Biotechnology Co, Ltd. (Walvax Biotechnology for short), founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it went public on the Shenzhen's Growth Enterprise Market (GEM), with the approval of China Securities Regulatory Commission (CSRC). Walvax Biotechnology employs about 863 people, including 161 for research and development. It has new-type vaccine research & development center and pilot base at Kunming High-tech Industrial Development Zone (located in Kunming, Yunnan province) as well as vaccine production bases at Yuxi Hi-Tech & New Industrial Development Zone (located in Yuxi, Yunnan province) and Taizhou National Medical Hi-Tech Development Zone (located in Taizhou, Jiangsu province). In addition, its marketing network covers 30 provinces or cities and more than 2000 regions or counties throughout China.? ?

1 Profile
2 Operation
3 Revenue Structure
4 Gross Margin
5 Client and Supplier
6 R&D and Investment
Vaccines on the Market and Capacity of Walvax Biotechnology
Revenue and Income of Walvax Biotechnology, 2007-2011
Revenue Breakdown of Walvax Biotechnology by Products, 2007-2011
Lot Release Quantity and Proportion of Walvax Biotechnology by Products, 2009-2012
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2011
Gross Margin of Walvax Biotechnology, 2007-2011
Walvax Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Top5 Clients and Their Revenue of Walvax Biological, 2011
Walvax Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011
Top5 Suppliers and Their Procurement Value of Walvax Biological, 2011
R&D Expenditure and Its Proportion to Revenue of Walvax Biotechnology, 2009-2011
New Vaccine Schedule of Walvax Biological as of March 31, 2012

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号